Free Deal Calculator

Calculate PROTAC Degrader Deal Values Instantly

Access real market data to price your degrader licensing deals with confidence and speed

Real-Time Market Data

Access current PROTAC deal benchmarks with 35% premium valuations above baseline therapeutics. Our database tracks Phase 2 upfronts from $60M-$250M and total deal values up to $2.5B.

Instant Accurate Valuations

Generate professional deal scenarios in minutes, not weeks. Our algorithms incorporate degrader-specific factors including target selectivity, tissue distribution, and competitive landscape positioning.

Built for BD Professionals

Created specifically for biotech executives negotiating degrader deals. Export presentation-ready reports that justify your valuation with market comparables and scientific rationale.

$1.8B

Average Total Deal Value

35%

PROTAC Premium vs Standard

47+

Degrader Deals Analyzed

95%

Valuation Accuracy Rate

How It Works

Input Your Degrader Profile

Enter target protein, development stage, and key differentiation factors including selectivity data and tissue penetration

Apply Market Benchmarks

Our system matches your asset against comparable PROTAC deals and applies current market premiums automatically

Generate Deal Scenarios

Receive multiple valuation models with upfront, milestone, and royalty structures ready for negotiation

Frequently Asked Questions

How does PROTAC degrader valuation differ from traditional small molecules?

PROTAC degraders command a 35% premium due to their novel mechanism, potential for tissue selectivity, and ability to target 'undruggable' proteins. Deal structures often include higher upfronts reflecting the platform potential.

What factors drive the highest PROTAC licensing valuations?

Key value drivers include validated target engagement, demonstrated tissue selectivity, oral bioavailability, and competitive differentiation. Assets targeting high-value oncology or neurodegeneration indications see premium valuations.

Are the deal benchmarks current with today's market conditions?

Yes, our database includes 2024 PROTAC deals and adjusts for current market conditions including investor sentiment, competitive landscape, and regulatory environment changes.

Can the calculator handle early-stage degrader programs?

Absolutely. The calculator includes preclinical and Phase 1 benchmarks, accounting for the higher risk-adjusted valuations while recognizing the significant upside potential of novel degrader mechanisms.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating